Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

susceptibility
Mo.A.40 1, Mo.B. 1362, No.6.223,
Pub.C. I I28,Th.A.4064,-1.8.4304,
buA. I140, Tu.A.200 1, [u.A.2036,
Tu.B.2 I198,lTu.6.269 1, We.B.3222
symptoms
Mo.B. 1 158, Mo.B. 1301, Mo.B. 330,
M o. B. I1334, M o B. 304, MoD. I1774,
Pub.B. 1097, OB. 19 1, I.1B.4 1I7,
10.B.4264, [h.8B.4267,,T[. 8.4305,
lu.B. I176, lu.B.2350, Tu.B.2384,
We.B.3 I146, \Ae.B.320 I, We.B.3296,
We.B.3340, We.B.3354, We.B.424,
We.C.3403, Wo.6.3409, We.C.343 7,
We.D.3 72
syncytium formation
Mo.A. I1073, Mo.A. 1 104, 1u.A. I162,
Tu.A.20 12, We.A.262
syncytium-inducing phenotype (SI)
Mo.B. I1345, Mo.B.293, 10.8.4328,
Tu.A. I104, bu.A. I 45,lTo.A.2047,3Tu A.206 I,
Tu.A.2074, T.B.2238, We.B.3283,
We.C.3438
synergy
Mo.A. I1103, Mo.B. 1369
syphilis
Mo.B.54 1, MoC. 1435, Ma.C. 14/9,
Mo.C. I1488, Mo.C. I1526, Mo.C. 161 2,
Mo.C.1613, Mo.C 1620, Mo.1621,
MoC. I1622, Mo.C. I1631, Mo.C. I1632,
Mo.C. 1638, Pob.A. 1005, Pub.B. 1049,
Pub.C. 1285, PoO.D. 1310, [0.8.4 I/O,
0 h.B.4260,1 hC 4651,Th.C.4705,
10.6.4743, [h.C.475 I,Iu.C.24 I18,
Tu.C.2684, We.B.3 185, We.B.3 186,
We.D.23 3
syringes
Mo.C.462, Mo.0.364, Mo.[).365,,Mo.0.366, Mo.D.600, Pub.C. 11I36,
-[u.C.2522,lu.C.2528, Wo.C.225,
Vv'e.C.3555, We.C.3562
V-cell epitope mapping
V ~e.A.3026, We.A 380, We.B. 1/6
T -cell growth factor (TCGF,
In terleukin-2)
T1h.A.4052, We.A.3064
T-cell homeostasais
We.A. 101,We.A.263, Wo.A.404,
We.B.3 120
T-cell lymphoma
lh.E1.4230, We.C.3430
T-ce II receptor-mediated proliferation
10.A4.4052, We.A.405
T-cel Is, SEE also CD4, CD8
MoA,.1037, Mo.A. 1049, Mo.B. 1316,
PuL..1070, Th.A. 140, 3h.A.400 /,
Th.A.-1008, Th.A.40 19,10.A.4020,
10.A.ai025,lh.A.4085, f[0.8.4329,
Tu.A.2 73,lii.B.52 I, We.A. 102,
We.A. 3003, We.A.3008, We.A.3038,
We.A.17059, We.A.306 I, We.A.3064,
We.A.3 085, We.C.3 393
T3 molecules
We.A. 102
T4 cells (helper cells). SEE CD4
Mo.A.40 5, Ma.C. 1551,We.A.382
T4 HeLa cells

terminal cart,, SEE palliative care
0.8. 1 90, Th. Ei.41I I 9, Th. D.5 178,
Th.D.5 179, [0.D.5180

testing, counselling
Mo.B. 1180, Mo.B. 1183, Mu.(.215,
Ma.D.1698, Mo.D. /501, Mu--.[).l1/55,
MoD. 1888, PuoOC. I204, PuOb.C.I1243,
Puib.C. 1244, PuoOC. 1245, Pub. 131,128,
PiiO.D. 1496, [h.C.4 I I, [..4591,
[0.6.4605,1 0.0.4608,31.6 -161 1,
lh.C.4612, 1.C64613, 11.6.4663,
Th.C.4664, 10(7C.4682, 1 h..4/ 12,
T0.C.4/ 16,11.6.4/22,10hC.4/3/
Th.C.4845,I10.3. 1 33,-101)D4921,
[0 0.4954, -I.0.4958,3T1I.D.5026,
1uBI13, 1u. B.2254,lu.C.202, 0..2 I1,
Tu.C.2474, lu.C.2482, Tu.C.2.559,
-[u.C.257 I,lu.C.45 I,Th.D 2768,
Tlu.D.2908, We.B.31I56, We. 31 /3,
We.C.3492,WAe.C. 3551, We.C. 3586,
We.C.3589, We.C.3593 We 1.3/I13,
We.D.3 /70, We.D.3805, \Nel.3838
testing, ethics
MoD. I/5O, Pu.C). I397, 1 h.[)495~8,
We.D.39 IS
testing, home kits
Mo.B. I1I83, [0.6.4606, 3u.A I1S I,
lu.B.21/4, We.C.3516
testing, mandatory
MoC.1552,30h.6.4621,V/Cl.3009,
We.C.35/ I, We.D.23 I, Ve 0.491
testing, other
Mo.B.I1181, Ma.C.120, Mo.. 155 I,
MoC. I1554, Ma.C. I1556, Mo.(.21 0,
Pub.A. 1005, Puh.A. I O6, PuO.C. 1155,
PuO.C. I24/, Pub..1310. II LA 1035,
10.6.4591,3 0.(.4596,1066.459/,
10.6.4601, T[0.6.4611, I1.1).5091,
100..5 18-4,3.A.2023,,lii.B.21 /I
testing, pregnancy
10.6.4 I I. [0.6.4592, 1 [.6.4594,
10.6.4599, T10.6.46 I I, lA. 4611,
10.6.46 15~, 6.6.245/, I l. 2 / I,
Tu.[.2/68, l.[)27/2, We.(.3516,
We.C.3583, We.C.3586,VWe.C.3589,
We.6 3590, We.6.3593, We.[3.49I
testing, premarital
MoD. I /50, PO.D1I384, 1 IL 8.4159,
TL..333, [u.6.45 I, We.(.351 6
testing, prisoners
10.6.460/, [.6.2632, hi.C.266-1,
We.D.3665
testing, voluntary
Mo.B. I1I80, Ma.C. 1422, ['l.6. 15.16,
Ma.C. I1629, Mo.6.2 10, Mo.6.21 2,
Mo.C.2 14, Mo.C.453, Mo.[. 1750,
MlaD. 1933, M.0.353, Pub.0 10,14,
Pub.C. I1I82, Pub.C. I1244, PoL. I 23/
Pub.C. 1264,1..43/3,166C.459 1,
[[.C.4595, 1.6.4601, I.(.4002.
[0.6.4604,10-.6.4605,1 0.460 /,
[h.C.4608, 106.461 I,41).C.4616,
1.6.4663,10h.0.4953,10h.0.5020,
noi.C.247/, lu.6.3 3 3\A/0(3501,
We.6.3529, We.[.360/
testis/epididymis
PoO.B. 1098, [0.13.41 05, ILL 3.2 381)
tetracycline analogs
10 0.5026
thalidomide

10.B.4329,10.C.4549, [0.0.5 I1I8,
10.0.5 I 55,Tu.A.2048,OLi.A.262, Tu.A 263,

lILL.21 12, ILL1321 13, lu.B.2 114,
1.B.2 118,1IL6.B.2 121,11.8.2133,
Tu.8B.2 148,ILu.B8.2 149, [u. B.2 183,
TII.B.2227, lu.B.2229, IL.B.2276,
L.B 2282,lLL.B.2322, ILL 8.2332,
Iu.8.2 352.Th.0 23,/2, II..285 I,
We.A. 3091 S\A 9.BI L7, We.B.292,
We.B.303,\/2e [1311/, uVe.8.31 18,
We.B.3 I125, We.B. 31 29, We.B.3 134,
We.B.3 I143, /e.B.3 I155, We.8.3 182,
We.B.3 I198, We.B.3226, 1Ne.8.3244,
We.B. 3250, VLe.B 32 / I, We.B.3284,
We.B.3323, We.B.3366, We.B.3374,
We.B.532, We.C.339/, We.D.6 12
thrombocytopenia
[loB. I1252, Mo.B. I1286, Mo.B. I1293,
[loB. I295, PLIOB. 107/,3 h.A.4087,
1 [..4108,10.0.4287, 10.8.4292,
We.B. I1I2, We 6.345 I
thrombotic thrombobo-cytopenic
purpura (TTP)
Mo.B. I1286, Mo.B. I1290, Mo.B. I1299
thrush, SEE candidiasis
iTl 8.2 197, VLe.B.3223
thymic humoral factor
10.8.4 195
thymidine
We.A. 302/, We.A.3028
chymosin
10.8.4 1/8
thymus
1.8.2 31 5, A/e A.264
TIBO derivatives
1.0.503 I
TMP-SMX
Mo.B. I1I97, Mo.B. 1204, PLLI.B.1I08 I,
1.. 182, O..228/, IL.B.2296, [u.B.2299,
IL.B.23O I, -OLi.B.4 I2,IL.B.4 I14, We.B.3226,
We.B.3230, We.B.33 19, We.8.3336,
We.B.552, Wo.C. 3458
tobacco
IL.B.2288
tolerance
Ma.D.252, (IL 0C.412., IL.B.2 I1I6, lu.B.2 I1/7,
We.A.S 12, We.C.3594
toxicity
Mo.A. I1086, MoBE)1 132, Mo.B. I1I89,
Mo.B.1204, Mo.B 1324, P1.. 1045,
30.8.1/0,1 h.B.4262,lu.B.2283,
We.A.30 10, We.A.5 12. We.B.3 122,
We.B.3 134
toxoplasmosis
M o.B.1I24 3, [Iao..310, Mo. B. 31I2,
[o.C. I 6/4,1 I.A.4(15(,1 [.A.4056,
[[.A.41)72, [IL.B. 1811,.8. 186,10h.8.4218,
[I.B.4234,l-0.8.428 I, WeA. I154,
iL.8B.2.264,-11.. 2 289, Tp. 8.412,
We.B.32 I'{, We.B.322 7, We.B.3228,
We.B.3229, We.B.3230, We.B.323I
tracing, contact, SEE partner
notification
Ma.6.1552
track, parallel, SEE parallel track
PLub..I459
traditional healers, SEE health care
personnel
M o.A. 1074, Mo. B. 300, MaD. 1/90,

We.C. I25, We.D.250, We.D.3636,
We.D.363/, We.D.3695, We.D.3701,

We.1.3/l /, We.[).3/S, We.D.3/82,
We.0.38 I2, We.[3.382/7
transcription
Mo.A.1023, Mo.A.1025, MaA 1026.
Mo.A 1035, Mo.A 500, MoAS50l,
Mo.A.502, Mo.A.503,1 0 A. 105, lILA. 146,
To.A.2076, IL.A.394, 1.A. 395.
We A.3088
transfection-neutralisation assay
We.B,194
transfer factor
VLe.C.346 I
transfusions, SEE also blood banks
Mo.B. I I SI, MoC.1536, Pub.C. 12/8,
10.8.1 /2,10.8. 175, We.B.3203,
We.D.388 I
transient seropositivity
ThA. 142,11.8.2 1/3
transmission cofactors, SEE cofactors,
transmission
Mo.A.40 I, Mo C, I498, Ma.C. 1603,
Mo.6.57 1, Mo.6.S /2., 10.0. 1322,
10.8.4167,1 0.C.4494,1lu.A.370,
lu.6.2445, O.C.2o89, We.C.3394,
We.C.35 /5
transmission efficiency
Mo.A.282, Mc.C.145/7, No.6.1498,
Ma.C. 1608, Mo.C.S /0, Ma C 5 /3,
P11.6. 1 136, P110.0. I22 I. IL.A 20(31.
3L.C.2424,lTu 6 2426,11.6.2436,
11..2694, We.C. 135, VWe.C.343 I,
We.D.38 14
transmission, SEE also specific routes
Mo.A.282, Ma.C. I1434, Ma.C. I1462,
Mo 6.1469, Mo.C 1495. Ma 6.1496,
MoC. I1536. Mo.C.573, Ma.D I /63,
Pub.C. 1 136, P11.6. I28,1,Th.A 4036,
10.6.4381,30 0S5026, [i.B.2122,
11.8 312,11.6 2426,111.1-.2461,
11..2563,11.6.2S97/, 1-1 6.2636,
11..2686,11.6.2693, 11..2694,
lu.D.2747, lu.D.2754, We 8.3229,
We.8.3255, We.B.)) / 7, We.6.2 I10,
We.6.351I7, We.[)3e55, We.D.3678
transplantation
Ma.C, 534,10.8 433 I
transsexuals, transgendered
Mo.D.600, Ma 0.601, M.0.603.
PijOC. 12S0, P1.. 146,10.0 4637,
b.C.4638, [0.6.1640.10 6C.46 /0,
lu.D.2903, [6.0.2953,16u.0.2954,
Tu.0.2967, LL.I3).60 I, We.0.3727
transvestites
Mo.0.601, Mo E.602, 1510 6.1235,
Pub.1447, [[.6.1638,1-0.0.466.
[u.C.2403
travellers
Mo.C.148/7, [1.[9.1695, PuO [3.1406,
Poub.1439, [0.6.4404,- [0.6.4529,
10.6.1830, 1 h.C.4838, TL.C.263o,
IL.C.264 1,111.1.2643,11.6.2645,
1Tu.C 2687,111.1.2909, [11 0.291 2.
We.D.37/4
treatment costs, SEE costs
Mo.B. IlI170, PuO.D. I1488, P11.0. I489,
10.8.4 193, 10.C.4 /52
trimethoprim-sulfamethoxazole, SEE

MoC. I166 I, P1u0.8. 1086, PLb.B. 1088,
Pu.B. 1089, Pub.B. I1090, P1u0.8.I109 I,

NO
0
v
c
03
a
c
0
N
Q)
102
c
501